ivWatch Awarded Breakthrough Technology Agreement with Premier

HAMPTON, Va.--()--ivWatch, LLC has been awarded a group purchasing agreement as a Breakthrough Technology with Premier. Effective Feb.1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the ivWatch Model 400, a continuous monitoring device for the early detection of peripheral IV (PIV) infiltrations.

"We are thrilled to be recognized by Premier as a Breakthrough Technology which accelerates the standard GPO process and enables us to educate more organizations about our technology offering a new standard of care for PIVs," said Scott Hensley, vice president of sales and business development at ivWatch. "This recognition is a testament to the need for a technology solution in hospitals for continuous IV monitoring for early detection of IV infiltrations and extravasations.”

This relationship enables Premier members to implement continuous monitoring of a patient’s PIV for evidence of infiltrations to improve patient outcomes. Intravenous therapy is a routine part of treatment for nearly 80 percent of patients in the U.S., yet more than 20 percent of these IVs may fail due to infiltration, risking both a serious drug delivery error and tissue damage. The ivWatch sensor technology is a solution to aid the clinician in early detection of this most serious event.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About ivWatch:

ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivwatch.com/

Contacts

ivWatch, LLC
Amara Betoney, 757-224-2606
Office: 855-489-2824 x7007
Mobile: 757-660-4949
amara.betoney@ivwatch.com

Release Summary

ivWatch, LLC has been awarded a group purchasing agreement as a Breakthrough Technology with Premier.

Social Media Profiles

Contacts

ivWatch, LLC
Amara Betoney, 757-224-2606
Office: 855-489-2824 x7007
Mobile: 757-660-4949
amara.betoney@ivwatch.com